Our Focus
Current treatment options for patients experiencing a stroke or heart attack are limited and delay the
re-establishment of blood flow.
TSci is dedicated to transforming standards of care, by bringing a simple intravenous biotherapy to the patient, closer to the time of onset.
TSci's bio-inspired solution is
-
A low dose, efficacious, safer dual thrombolytic Rx
-
Based on a clinically validated mechanism
-
To be given on suspicion of a stroke or heart attack
Clinical Trials
TSci recently completed a Phase 1 clinical study confirming the safety and tolerability of its novel tPA / HisproUK dual regimen.
TSci's dual regimen is currently being tested in a Phase 2 clinical trial in ischemic stroke patients.
Science
tPA's biological role is limited to degrading the surface of the clot.
With TSci’s regimen, once this occurs, the small amount of tPA used is rapidly cleared from the blood flow. HisproUK, TSci's compound, exclusively targets the now degraded clot and dissolves it.
Should there be no degraded clot, as in the case of stroke mimics or a hemorrhagic stroke, HisproUK will remain safely in its inactive pro enzymatic form before being cleared in minutes from the blood flow.
TSci's thrombolytic regimen could therefore be given safely on simple suspicion of an ischemic stroke, as soon as possible after stroke onset.
Team
Management & Directors
Board member
_edited_edited.jpg)
Board member
Advisory Board
Chairman of the Court,
London School of Hygiene
& Tropical Medicine
Non-Executive Chairman,
Cocoon Biotech
Professor of Medicine, Hematology
Adjunct Professor, Neurology,
Washington University
Senior Lecturer,
Harvard Medical School, Former Chief Medical Officer, Chairman & Founder, InfraReDx
1985 Nobel Peace Prize
President & CEO,
Baim Institute
for Clinical Research
Professor of Medicine,
Harvard Medical School
Chairman & Founder, PERFUSE
News
October 4, 2024
September 24, 2024
May 22, 2023
-
No significant difference between groups in All ICH, i.e.: asymptomatic + symptomatic ICH, the primary endpoint.
-
Secondary endpoints show positive trends in favor of a safe, low dose dual therapy
-
No symptomatic ICH
-
Less disability
-
No fibrinogen depletion, i.e.: less risk of bleeding
-
Authors conclude further exploration in more severe stroke patients is warranted.
October 29, 2021
Thrombolytic Science Awarded US Patent on its Novel Clot-dissolving Therapy
February 10, 2021
September 5, 2018
NeurologyLive: Phase II Trial of HisproUK, Low-Dose tPA Dual Therapy for Ischemic Stroke Initiated
November 15, 2017
Thrombolytic Science appoints Michael Woehler, PhD, Chairman of the board
September 18, 2017
Publications
VIEW> Gurewich V., Segarnick D. Reperfusion of Ischemia in the Heart or Brain. JPET. 2025.
VIEW> Gurewich V., Segarnick D. Fibrinolysis was Replaced Before it was Understood. KARGER 2025.
VIEW> Van der Ende, N et al. Safety and Efficacy of Dual Thrombolytic Therapy With Mutant Prourokinase and Small Bolus Alteplase for Ischemic Stroke, A Randomized Clinical Trial. JAMA Neurol. 2023.
VIEW> Gurewich V. Therapeutic Fibrinolysis: How Efficacy and Safety Can Be Improved. JACC 2016.
VIEW> Bogarty P, Brophy J. STEMI Treatment 2016: Is Outcome Improvement Stalling and If So, Why? DOI 2016.
VIEW> Pannell R, Li S, Gurewich V. Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK. PLoS One. 2015; 10(3):e0122018.
VIEW> Tomasi S, Sarmientos P, Giorda G, Gurewich V, Vercelli A. Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke. PLoS One. 2011; 6(7):e21999
Contact
Thrombolytic Science, LLC
One Broadway, 14 FL
Cambridge, MA 02142